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Viral protein R (Vpr) of human immunodeficiency virus type 1 (HIV-1) is an accessory protein that plays an
important role in viral pathogenesis. This pathogenic activity of Vpr is related in part to its capacity to induce
cell cycle G2 arrest and apoptosis of target T cells. A screening for multicopy suppressors of these Vpr activities
in fission yeast identified heat shock protein 70 (Hsp70) as a suppressor of Vpr-induced cell cycle arrest. Hsp70
is a member of a family of molecular chaperones involved in innate immunity and protection from environ-
mental stress. In this report, we demonstrate that HIV-1 infection induces Hsp70 in target cells. Overexpres-
sion of Hsp70 reduced the Vpr-dependent G2 arrest and apoptosis and also reduced replication of the
Vpr-positive, but not Vpr-deficient, HIV-1. Suppression of Hsp70 expression by RNA interference (RNAi)
resulted in increased apoptosis of cells infected with a Vpr-positive, but not Vpr-defective, HIV-1. Replication
of the Vpr-positive HIV-1 was also increased when Hsp70 expression was diminished. Vpr and Hsp70 coim-
munoprecipitated from HIV-infected cells. Together, these results identify Hsp70 as a novel anti-HIV innate
immunity factor that targets HIV-1 Vpr.
Heat shock proteins (HSPs) are produced in cells in re-
sponse to a range of stress-related stimuli, including heat, UV
radiation, and microbial/viral infections. In addition to previ-
ously recognized activity of HSPs as facilitators of protein
folding and chaperones, recent studies revealed unique prop-
erties of HSPs in generating specific immune responses against
cancers and infectious agents (reviewed in reference 3). More-
over, binding of HSPs to human immunodeficiency virus type
1 (HIV-1) proteins can enhance antiviral immunity, including
natural killer (NK) cell,  T-cell and cytotoxic T-lymphocyte
activities against HIV-1-infected cells (4). HSPs Hsp27 and
Hsp70 are selectively expressed early after HIV-1 infection
(50), suggesting that these proteins might be a part of the
cellular innate antiviral immune responses. However, the spe-
cific targets of HSPs and their role in responses to HIV infec-
tion remain unclear.
HIV-1 viral protein R (Vpr) is highly conserved among HIV
isolates, simian immunodeficiency virus, and other lentiviruses
(47, 48). Accumulating evidence suggests that Vpr plays an
important role in the viral life cycle and pathogenesis. For
example, Vpr is required for efficient viral infection of macro-
phages, which serve as viral reservoirs throughout the course of
infection (8, 15, 19, 20, 43). Chimpanzees and human subjects
infected with the Vpr-defective viruses show slower disease
progression, often accompanied by reversion of the mutated
vpr gene back to the wild-type phenotype (27, 29, 40, 54).
Rhesus monkeys infected with a pathogenic SIVmac239 strain,
which carries two Vpr-related genes (vpr and vpx) believed to
arise by duplication, did not get sick when both vpr and vpx
genes were inactivated, although inactivation of either gene did
not significantly affect disease progression (14). Interestingly,
functionally defective Vpr mutations were found to be associ-
ated with long-term nonprogressive HIV infection and were
shown to impair induction of apoptosis by Vpr (40, 54).
Vpr displays several distinct activities in the host cells. These
include cytoplasmic-nuclear shuttling (19), induction of cell
cycle G2 arrest (18), and cell killing (41). The cytoplasmic-
nuclear shuttling of Vpr reflects its surmised role in nuclear
transport of the viral preintegration complex, which is critical
for efficient infection of nonproliferating cells, such as macro-
phages (7, 19, 38). The cell cycle G2 arrest induced by Vpr is
thought to suppress human immune functions by preventing
T-cell clonal expansion and to provide an optimized cellular
environment for maximal levels of viral replication (15, 37). In
addition, Vpr exerts a proapoptotic activity on an infected cell
(6, 12, 13, 34). These Vpr-specific activities are functionally
independent of each other and can be observed in a variety of
eukaryotic cells (5). Consistently, Vpr behaves very similarly in
fission yeast and mammalian cells, making fission yeast a par-
ticularly useful model to study the Vpr effects (reviewed in
reference 55). Using this model, we searched for suppressors
of Vpr activity and pulled out several HSPs as suppressors of
G2 arrest in fission yeast. Analysis of the effects of one such
protein, Hsp70, on Vpr activities in HIV-1-infected cells is
presented in this report.
MATERIALS AND METHODS
Reagents. The Hsp70 and the Hsp27 enzyme-linked immunosorbent assay
(ELISA) kits were from Stressgen Biotechnologies (Victoria, British Columbia,
Canada). The Annexin V-fluorescein isothiocyanate (FITC) Apoptosis Detec-
tion Kit II was purchased from BD Biosciences PharMingen (San Diego, Calif.).
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Mouse monoclonal antibody (MAb) against human Hsp70 was from Calbiochem
(San Diego, Calif.), and goat polyclonal antibody against human Hsp70 (K-20)
and mouse anti-c-Myc (9E10) MAb were purchased from Santa Cruz Biotech-
nology, Inc. (Santa Cruz, Calif.). Rabbit polyclonal anti-Vpr antibody was a kind
gift of Josephine Sire (INSERM, Marseille, France). Hsp70/Myc plasmid ex-
pressing Myc-tagged Hsp70 (45) was provided by Richard Vile (Mayo Clinic,
Rochester, Minn.).
Cell cultures. HEK 293T and HeLa cells were obtained from the American
Type Culture Collection (Manassas, Va.) and maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% (vol/vol) fetal bovine serum
(FBS) (Bio Whittaker), 100-U/ml penicillin, and 100-U/ml streptomycin. The
293T-632 cell line was derived from the 293T cells by introducing a heterodimer
of the modified ecdysone receptor (VgEcR) and the retinoid X receptor (RXR)
(57). The transfected 293T-632 cells expressing vpr and Hsp70 were selected with
Geneticin (750 g/ml; Mediatech) for vpr cloned on the pZY-1 plasmid and
hygromycin (200 g/ml) for Hsp70 cloned on the pZH-1 plasmid. Gene expres-
sions in 293T-632 cells were induced by addition of 1 M muristerone A (57). H9
cells (CD4 T-cell line) stably expressing HSP70 were transfected with HSP70-
expressing pcDNA3.1 plasmid and selected with zeocin (100 g/ml).
Fission yeast cells were transformed using lithium acetate transformation
procedure and cultured on a selective medium as described previously (53). Cells
carrying the leu1- or ura4-selectable plasmids were maintained on agar plates of
standard Edinburgh minimal medium (EMM) with appropriate amino acid sup-
plements without leucine or uracil. Thiamine was added at 20 M to repress
gene expression from a strongly regulated nmt1 (no message in thiamine) pro-
moter (53). All cells were normally grown at 30°C with constant shaking at 200
rpm. Cells were examined approximately 24 h after gene induction.
RNAi. A 21-nucleotide-pair Hsp70 short interfering (si) DNA/RNA duplex
(DNA-RNA hybrid) was chemically synthesized and purified by TriLink Bio-
Technologies, Inc. (San Diego, Calif.). The DNA strand of the duplex was
homologous to the Hsp70 DNA sequence (GenBank accession no. M11717):
5-AAGGCCAACAAGATCACCAT-3. The antisense RNA strand was 5-AU
GGUGAUCUUGUUGGCCU(dTdT)-3]. The control duplex carried three nu
cleotide substitutions (GCC to AAA in the DNA strand). Transfection of HeLa
cells with these siDNA/RNA duplexes was performed in six-well plates with
Oligofectamine (Invitrogen, Carlsbad, Calif.) according to the manufacturer’s
protocol. Five hours after transfection, culture medium containing transfection
complexes was removed; cells were then washed with phosphate-buffered saline
(PBS) twice and infected with recombinant HIV-1.
Preparation of HIV stocks and infection. Phytohemagglutinin (PHA)-acti-
vated peripheral blood mononuclear cells (PBMCs) were infected with HIV-1
LAI, a T-cell line-adapted strain of the virus. Viral titers were normalized
according to reverse transcriptase activity. After a 2 h of adsorption, cells were
washed with RPMI 1640 without FBS, seeded at a density of 106 cells/ml, and
cultured for 7 days in RPMI 1640 supplemented with 10% FBS (vol/vol).
Recombinant virus stocks for infection of HeLa CD4 cells (MAGI) were
generated by transfecting 293T cells with Vpr or Vpr NLHXB infectious
clones (38) with or without a vector encoding the Env protein of the amphotropic
murine leukemia virus [pcDNA-Env(MLV); plasmid provided by N. Landau] by
using Metafectene (Biontex). Seventy-two hours after transfection, recombinant
virus particles were harvested and purified from the culture media by centrifu-
gation through 30% sucrose cushion in PBS at 24,000 rpm in a Beckman SW-28
rotor for 2 h at 4°C. Viral titers were normalized for virus content by p24 ELISA
(NEN Life Science, Inc., Boston, Mass.). Infection was performed in six-well
plates by spinoculation according to a published protocol (36).
Analysis of G2 arrest. For cell cycle analysis of human cells, approximately
1.5  106 cells were suspended in 500 l of PBS and fixed by adding 5 ml of
anhydrous ethanol. After an overnight incubation at 4°C, cell pellets were
washed and incubated for 30 min in 500 l of PBS containing 50-g/ml pro-
pidium iodide (Sigma) and 1-mg/ml boiled RNase A (Sigma). The stained cells
were analyzed for red fluorescence on a FACSCalibur (Becton Dickinson) flu-
orescence-activated cell sorter (FACS) by using Cell Quest software.
For analysis of Vpr-induced G2 arrest of fission yeast cells, a vpr-induced cell
elongation (commonly known as the “cdc phenotype”) was used. The cdc phe-
notype is the result of a cell cycle G2/M delay or arrest (11, 33). Cell images were
first captured on a Leica microscope, and the cell length was determined by using
OpenLab software.
Flow cytometric analysis of apoptotic cells. For quantification of apoptotic
cells, FACS analysis of infected HeLa cells was performed with Annexin V-FITC
Apoptosis Detection Kit II (BD PharMingen). Data were analyzed with the Cell
Quest program.
Coimmunoprecipitation assays. HeLa CD4 (MAGI) cells transfected with
Myc-tagged Hsp70-encoding plasmid and infected with HIV-1 were harvested,
washed with PBS twice, and lysed in immunoprecipitation buffer containing
5.0 mM CHAPS {3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfon-
ate}, 50 mM NaCl, and 20 mM Tris (pH 7.5), according to reference 31. Equal
amounts of the lysates (according to protein content) were immunoprecipitated
with anti-Hsp70 or anti-Vpr polyclonal antibody and analyzed by Western blot-
ting with polyclonal anti-Vpr or mouse anti-Hsp70 or anti-Myc MAbs.
RESULTS
Hsp70 suppresses the Vpr-induced cell cycle arrest. Because
the yeast Hsp70 was pulled out in our search for suppressors of
Vpr activity in Schizosaccharomyces pombe (unpublished re-
sult), we first tested the effect of Hsp70 on cell cycle in fission
yeast. The expression vector for the fission yeast or mammalian
Hsp70 was introduced into the RE076 S. pombe strain, which
carries a single integrated copy of F34Ivpr under the control of
an inducible nmt promoter (11). In the fission yeast, the Vpr
protein with an F34I mutation is attenuated in the ability to
induce cell death but fully retains the capacity to induce cell
cycle G2 arrest (11). As shown in Fig. 1A (top right panel),
expression of F34Ivpr-induced cell elongation typical of a cell
cycle G2/M delay, which is commonly known as the “cdc phe-
notype” (11, 28, 33). Cell length measurements after 24 h of
gene induction indicated that vpr-expressing cells had an aver-
age length of 18.9  3.0 m during log-phase growth, as com-
pared to 11.8  2.4 m in vpr-repressing cells (top left panel).
However, the Vpr-induced cell elongation was strongly sup-
pressed when a cDNA clone encoding either a fission yeast
(middle row panels) or the mammalian Hsp70 (bottom row
panels) was expressed from the nmt1 promoter. Wild-type Vpr
induces cell cycle G2 arrest and leads to cell death. A more
heterogeneous size distribution in cells expressing vpr is likely
explained by death of some cells due to residual cell-killing
activity of F34Ivpr. A small proportion of elongated cells in
cultures transfected with Hsp70 constructs likely represents
cells that did not express the gene, as, despite culturing trans-
formed cells on a selective medium, there is always a small
percentage left with an untransformed phenotype (53). Impor-
tantly, Hsp70 did not affect the length of cells where Vpr had
not been induced (left panels), indicating that Hsp70 specifi-
cally counteracted Vpr-induced G2 arrest in yeast cells. Thus,
overexpression of S. pombe or mammalian Hsp70 in yeast
inhibited Vpr-induced cell cycle G2 arrest.
To extend this result to mammalian cells, we used an episo-
mal system for ecdysone-inducible vpr expression described
recently by Zhou and Ratner (57). In this system, vpr and a
gene of choice (Hsp70 in our case) are maintained as episomes
in 293T cells as part of pZY-1 or pZH-1 vectors, respectively,
and can be induced by muristerone A. Results of the FACS
analysis of such cells after propidium iodide staining of DNA
are shown in Fig. 1B. Results are recalculated as a G2/G1 ratio
of induced relative to cells cultured without the inducer: R 	
[G2/G1 (induced)]/[G2/G1 (uninduced)]. If this value is close to
1, the induced proteins do not affect the cell cycle distribution,
while a value of 
1 indicates induction of the G2 arrest. A
G2/G1 ratio of 1.08 of cells carrying empty vectors in cultures
grown with the inducer relative to cultures grown without the
inducer (Fig. 1B, upper panels) indicates that muristerone A
did not alter normal cell cycle distribution in cells (57). In
contrast, a significant increase in this ratio, 2.15, observed in
cells carrying vpr-expressing vector and grown with muris-
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terone A indicated that vpr gene expression induced a G2
arrest of the cell cycle (Fig. 1B; middle row). Coexpression of
mammalian Hsp70 with vpr blocked the Vpr-induced G2 arrest
(G2/G1 ratio, 0.97; Fig. 1B, bottom row). Western blot analysis
showed that both Vpr and Hsp70 were properly produced
upon induction with muristerone A. The presence of small
amounts of Hsp70 in uninduced cells is consistent with its role
in normal cellular metabolism (25).
To analyze the effect of Hsp70 on Vpr-induced G2 arrest in
the context of HIV-1 infection, we transfected HeLa cells with
an Hsp70-expressing vector and infected them with an MLV-
pseudotyped HIV-1. The efficiency of transfection of HeLa
and derivative MAGI cells was routinely 60 to 70%, as mea-
sured by flow cytometry of samples in which a green fluores-
cent protein (GFP)-expressing vector was added to transfec-
tion mixtures. It should be noted that a high virus inoculum
(1.1  107 cpm of reverse transcriptase activity per 106 cells)
was used in this experiment to bring the percentage of infected
cells close to 100%. Results presented in Fig. 1C demonstrate
a dramatic decrease (5.19-fold) in the G2/G1 ratio in Hsp70-
transfected culture infected with a Vpr-positive virus (panel f)
as compared to culture transfected with an empty vector (panel
e). Some decrease in G2 cells was observed in mock-infected
cultures (panels a and b, relative G2/G1 ratio of 1.42) or cul-
tures infected with a Vpr-deficient virus (panels c and d, rela-
tive G2/G1 ratio of 1.19), but it was substantially smaller.
Taken together, these results indicate that Hsp70, when
overexpressed in an HIV-infected cell, partially reverses the
Vpr-induced G2 arrest of the cell cycle progression.
Suppression of Hsp70 expression by RNAi increases the
Vpr-dependent apoptosis. To determine whether Hsp70 re-
duces Vpr effects during natural HIV-1 infection, we first an-
alyzed the level of Hsp70 in cells infected with HIV-1. Consis-
tent with the results of Brenner and coauthors (50), HIV-1
infection of both MAGI cells (modified HeLa cells expressing
the CD4 receptor) and PBMCs resulted in a significant in-
crease in the levels of intracellular Hsp70: from 0.3  0.04
pg/cell to 1.5  0.17 pg/cell (P 	 0.009) 48 h after infection of
MAGI cells and from 0.1  0.026 pg/cell to 0.3  0.021 pg/cell
(P 	 0.014) 96 h after infection of PBMCs.
To inhibit Hsp70 expression, we employed the RNAi ap-
proach (9). Hybrid DNA/RNA molecules (siDNA/RNA) were
used for silencing as such molecules have been shown to exert
a much greater effect in both duration and degree of suppres-
sion than conventional siRNA (26). MAGI cells were trans-
fected with siDNA/RNA against Hsp70 or control siDNA/
RNA and infected with a Vpr-positive or Vpr-defective HIV-1
construct. The specificity of Hsp70 siDNA/RNA was con-
FIG. 1. Hsp70 suppresses Vpr-induced cell cycle G2 arrest. (A) Suppression of Vpr-induced G2 arrest in fission yeast. Vpr-induced cell
elongation was used here as an indication of cell cycle G2 arrest (11). RE076 is a fission yeast strain that carries a single integrated copy of F34Ivpr
(11, 56). RE076Vector denotes the RE076 strain transformed with the pYZ1N vector control. RE076spHsp70 and RE076mHsp70 are
RE076 strains transformed with fission yeast or mammalian Hsp70, respectively. vpr-Off, vpr gene expression suppressed; vpr-On, vpr gene
expression induced. (B) Hsp70-mediated suppression of Vpr-induced G2 arrest in 293T-632 cells. Vpr-induced G2 arrest was measured by flow
cytometric analysis after staining DNA with propidium iodide. The extent of G2 arrest was evaluated by the relative G2/G1 ratio (shown in the
right-hand panels) between cells cultured in the presence and absence of the inducer (muristerone A): R 	 [G2/G1 ( inducer)]/[G2/G1 (
inducer)] (57). A Western blot (bottom) shows coexpression of HIV-1 vpr and mammalian Hsp70 genes in muristerone A-induced 293T-632 cells.
pZY-1 is a vector used for vpr expression, and pZH-1 was used for mHsp70 expression. Both vectors are induced by addition of 1 M muristerone
A (57). Results are shown for one representative experiment out of three performed. (C) Hsp70 suppresses Vpr-induced G2 arrest in HIV-1-
infected cells. MAGI cells were transfected with an Hsp70-expressing vector and 24 h after transfection were infected with a Vpr-positive or
Vpr-negative MLV-pseudotyped HIV-1. G2 arrest was analyzed 48 h after infection by flow cytometry as in panel B. The effect of Hsp70 was
evaluated by relative G2/G1 ratio (shown in left panels) in cells transfected with Hsp70-expressing vector and control cells: R 	 [G2/G1
(Hsp70)]/[G2/G1 (Hsp70)]. Results are shown for one representative experiment out of two performed.
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firmed by analysis of Hsp70 and Hsp27 expression with ELISA
kits: while levels of Hsp70 were decreased, the level of Hsp27
was not affected (Fig. 2A). It should be noted here that the
human Hsp70 family includes a number of isoforms that still
differ in primary nucleotide sequence (44), and several of these
isoforms are expressed upon HIV-1 infection (50). While we
targeted the main cytosolic form of Hsp70, we did not expect
to completely knock out expression of all inducible Hsp70
forms.
The effect of siDNA/RNA on G2 arrest was calculated as a
relative G2/G1 ratio between cells transfected with control and
Hsp70 siDNA/RNA: R 	 [G2/G1(Hsp70 siDNA)]/[G2/G1
(control siDNA/RNA)]. In mock-infected cells, this ratio was
1.1, indicating that Hsp70 siDNA/RNA did not change the cell
cycle distribution (Fig. 2B, upper panels). A close ratio (R 	
0.9) was found in cells infected with a Vpr-deficient virus
(middle row of panels). In cells infected with a Vpr-expressing
HIV-1 construct, which induced substantial G2 arrest in con-
trol cells, Hsp70 siDNA/RNA slightly increased the number of
G2-arrested cells, as evidenced by the relative G2/G1 ratio of
1.3 (bottom panels). While this effect was relatively small, it
was reproduced in two independent experiments.
Following the Vpr-induced G2 arrest, cells go into apoptosis
and die (41). The mechanism of Vpr-induced apoptosis is
unclear (22, 42, 51) and may or may not be related to the
mechanism of G2 arrest by Vpr (10, 35). Importantly, the
apoptotic activity of Vpr is a recognized pathogenic factor in
HIV-1 infection, contributing significantly to HIV-induced apo-
ptosis of infected and bystander cells (2, 23, 29, 42). Given that
Hsp70 reduces Vpr-induced G2 arrest, we investigated the
effect of Hsp70 on Vpr-dependent apoptosis associated with
HIV-1 infection. We used the same approach as for analysis of
cell cycle progression (Fig. 2B), except that the percentage of
apoptotic cells in cultures treated with Hsp70 siDNA/RNA
relative to cultures treated with control siDNA/RNA was cal-
culated: R 	 [M2(Hsp70 siDNA/RNA)]/[M2(control siDNA/
RNA)]. Consistent with previous reports (34), infection of
MAGI cells transfected with control siDNA/RNA with Vpr-
expressing HIV-1 increased the percentage of apoptotic cells
(M2 gate on the histogram) from 6.61% observed in mock-
infected culture to 16.90% (left panels in Fig. 2C). The per-
centage of apoptotic cells was dramatically increased in cul-
tures transfected with Hsp70 siDNA/RNA and infected with
Vpr-expressing HIV-1 (R 	 2.22; bottom panels). No such
increase was observed in mock-infected cultures (R 	 1.14),
and only a minor increase was detected in cultures infected
with Vpr-deficient virus (R 	 1.45). These results suggest that
the antiapoptotic activity of Hsp70 preferentially targets Vpr-
specific apoptosis.
The effect of Hsp70 on HIV-1 replication. The ultimate pur-
pose of HIV-1 accessory genes is to provide replication advan-
tage to the virus. The capacity of Vpr to induce G2 growth
FIG. 2. RNAi-mediated suppression of Hsp70 expression enhances Vpr-specific apoptosis of HIV-1-infected cells. MAGI cells were transfected
with Hsp70-specific or control siDNA/RNA duplexes and then infected with Vpr-negative (Vpr) or Vpr-positive (Vpr) HIV-1 or mock infected.
(A) Hsp70 and Hsp27 were quantified in cell lysates by ELISA 24 h after infection. Results are the mean  standard error of triplicate wells.
(B) Cell cycle distribution was analyzed by FACS 48 h after infection as in Fig. 1B. The effect of siDNA/RNA was evaluated by the ratio of G2/G1
in cultures transfected with control siDNA/RNA to G2/G1 in cultures transfected with Hsp70-specific siDNA/RNA (shown in the left column
panels). Results are representative of two independent experiments. (C) Apoptotic cells were stained with Annexin V-FITC and analyzed by flow
cytometry 24 h after infection. The effect of siDNA/RNA was evaluated by the ratio of apoptotic cells in cultures transfected with control and
Hsp70-specific siDNA/RNA (shown in left column panels). Results are representative of two independent experiments.
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arrest has been implicated as a positive factor for HIV-1 rep-
lication in vitro (16, 19). Our finding that Hsp70 counteracts
this Vpr activity suggested that it may also reduce HIV-1 rep-
lication. We first tested this premise in MAGI cells transfected
with Hsp70 siDNA/RNA. HIV-1 replication was analyzed 48 h
after infection of MAGI cells by flow cytometry after staining
the intracellular p24 (Fig. 3A) and by measuring extracellular
p24 (Fig. 3B). It should be noted here that staining of intra-
cellular p24 in this experiment does not detect all infected
cells, as p24 expression in many cells at 48 h postinfection (this
time point was chosen to correlate analysis of virus replication
and cell cycle distribution) does not yet reach the levels that
can be detected by this assay (32). A substantial increase in
both the number of p24-expressing cells (from 10% to 19.5%)
and the amount of extracellular p24 (from 45 ng/ml to 150
ng/ml) was observed in cultures transfected with Hsp70
siDNA/RNA and infected with a Vpr-positive HIV-1 as com-
pared to cultures transfected with control siDNA/RNA. No
such increase was seen with a Vpr-deficient virus (Fig. 3B),
demonstrating that the observed effect was Vpr dependent.
Conversely, overexpression of Hsp70 reduced replication of
the Vpr-positive HIV-1 in MAGI cells without affecting repli-
cation of the Vpr-negative virus (Fig. 3C). Of note, the MAGI
cells were transiently transfected with the Hsp70-expressing
vector; therefore, the experiment was not continued beyond
the 96-h time point, when expression of Hsp70 started to sub-
side (not shown). To determine the effects of Hsp70 on spread-
ing HIV-1 infection, we analyzed replication of Vpr-positive
and Vpr-negative viruses in H9 cells (a CD4 T-cell line)
stably transfected with Hsp70. Results presented in Fig. 3D
demonstrate that replication of Vpr-positive, but not of a Vpr-
deficient HIV-1, was reduced in Hsp70-transfected cells rela-
tive to cells transfected with an empty vector.
We conclude that Hsp70 exerts a certain degree of protec-
tion against HIV-1 infection.
Hsp70 coimmunoprecipitates with Vpr. The inhibitory effect
of Hsp70 on such distinct activities of Vpr as G2 arrest and
apoptosis suggested that Hsp70 might bind to Vpr, thus affect-
ing its interaction with cellular partners. To test this possibility,
we immunoprecipitated Hsp70 from HIV-1-infected MAGI
cells and analyzed the immunoprecipitate by using Vpr- and
Hsp70-specific antibodies. As shown in Fig. 4A, Vpr was de-
tected in the immunoprecipitates from cells infected with a
Vpr-positive, but not with Vpr-defective, HIV-1. No Vpr was
detected when immunoprecipitation was performed with an
antiactin antibody (not shown), demonstrating specificity of
the observed interaction. In a reciprocal experiment, Vpr was
immunoprecipitated from MAGI cells transfected with myc-
tagged Hsp70 and infected with Vpr-positive HIV-1. Analysis
using anti-Myc antibody revealed that Hsp70 was coimmuno-
precipitated with Vpr (Fig. 4B). No actin was found in the
immunoprecipitates (not shown), confirming the specificity
FIG. 3. Analysis of Hsp70 effects on HIV-1 replication. (A) MAGI cells were transfected with control or Hsp70 siDNA/RNA. Twenty-four
hours after transfection, cells were infected with HIV-1 or mock infected. HIV-1 replication was analyzed 48 h after infection by staining
intracellular p24 essentially as described previously (32). The percentage of p24-positive cells is shown. For mock-infected cells, only results with
Hsp70 siDNA/RNA-transfected cells are presented. (B) The experiment was performed as in panel A, except that cells were infected with
Vpr-positive (Vpr) or Vpr-negative (Vpr) HIV-1 and extracellular p24 was measured by ELISA. Results show mean  standard deviation of
three independent wells. (C) Triplicate cultures of MAGI cells, transfected with either an Hsp70-expressing (vectorHsp70) or an empty vector,
were infected with Vpr-positive or Vpr-negative HIV-1. Virus replication was measured at indicated times after infection by reverse transcriptase
activity in culture supernatants. Results are presented as means  standard deviation. (D) Triplicate cultures of H9 cells stably transfected with
Hsp70-expressing (vectorHsp70) or an empty vector were infected with Vpr-positive or Vpr-negative HIV-1. p24 in culture supernatants was
measured at indicated time points after infection by ELISA. Results are presented as the mean  standard deviation. The inset in the left panel
shows Western blot analysis of Hsp70 and -actin proteins in transfected H9 cultures.
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of the observed interaction. These results demonstrate that
Hsp70 interacts with Vpr within an HIV-infected cell. There-
fore, Hsp70-Vpr interaction, which was initially observed in
macrophages (21), can be extended now to other cell types.
DISCUSSION
In this report, we demonstrate that Hsp70 is induced in
HIV-infected cells to target HIV-1 Vpr and reduce Vpr-de-
pendent G2 arrest and apoptosis. Hsp70 also reduces HIV-1
replication in a Vpr-dependent fashion. Therefore, Hsp70 ap-
pears to function as a component of the innate cellular immu-
nity against HIV-1. This new activity of Hsp70 is distinct from
previously described mechanisms involving binding of Hsp70
to viral complexes to facilitate antigen presentation and en-
hance antiviral immunity, including antibody-dependent cellu-
lar cytotoxicity and cytotoxic T-lymphocyte-mediated killing of
HIV-1-infected cells (4). While the latter activities of Hsp70
are related to the recognized ability of these proteins to stim-
ulate antigen-presenting cells (3), the new role of Hsp70 iden-
tified in this report is to neutralize deleterious activities of a
particular HIV-1 protein, Vpr. Interestingly, Vpr has been
shown recently to be targeted by another intracellular chaper-
one molecule, cyclophilin A (52). However, in contrast to
Hsp70, which inhibits Vpr activities in target cells, CypA ac-
tually assists Vpr expression in virus-producing cells and does
not affect Vpr packaging. It remains to be determined whether
Hsp70 bound to Vpr in a producing cell diminishes Vpr pack-
aging. Another interesting question for future studies is wheth-
er Vpr contributes to Hsp70 incorporation into HIV-1 virions
and what is the role (if any) of virion-associated Hsp70 in the
new cycle of infection. Previous study (17) demonstrated that
Gag is sufficient for Hsp70 incorporation, which, together with
an established role of Vpr in the early steps of infection, argues
that Vpr does not get in contact with Hsp70 within the virion.
The human Hsp70 family encompasses at least 11 genes that
encode a group of highly related proteins, which include both
cognate and highly inducible members located in various sub-
cellular compartments (46). Hsp70, as well as its constitutively
expressed and only slightly inducible form, Hsc70, is located in
the cytoplasm, and therefore both forms have the opportunity
to interact with Vpr. Results of subtractive immunoprecipita-
tion suggest that both Hsp70 and Hsc70 can bind to Vpr (S.
Iordanskiy, unpublished observation). Thus, it is likely that
several Hsp70 isoforms contribute to the anti-Vpr activity in
HIV-1-infected cells. Interestingly, suppression of Hsp70 by
RNAi had little effect on Vpr-mediated G2 arrest but substan-
tially increased Vpr-specific apoptosis in HIV-1-infected cell
cultures (Fig. 2). This result suggests that the Hsp70 isoform
targeted by siDNA/RNA used in our experiments has specific-
ity for apoptosis-related factors activated by Vpr. Therefore, in
addition to direct interaction with Vpr (Fig. 4), Hsp70 isoforms
may reduce Vpr-specific effects by targeting Vpr-activated sig-
naling pathways that lead to G2 arrest or apoptosis.
The anti-HIV activity of Hsp70 reported here seems at odds
with our previous observation that Hsp70 can replace Vpr in
HIV-1 nuclear import (1) and is therefore expected to stimu-
late HIV-1 nuclear translocation and replication. It should be
noted that the current report deals with proliferating cells,
where Vpr-dependent nuclear translocation is less critical for
HIV-1 replication than in such nonproliferating cells as mac-
rophages (49). Therefore, while active nuclear import seems to
be important for HIV-1 infection of both proliferating and
nonproliferating cells (24), it remains possible that Vpr does
not contribute much to HIV-1 nuclear transport in dividing
cells. In addition, the effect on viral replication was tested in
this study by measuring intracellular or extracellular p24, thus
reflecting the cumulative effect of pre- and postintegration
steps of viral replication. Inhibition of postintegration steps
could overcome any stimulatory effect of Hsp70 on HIV-1
nuclear import.
The results presented in this report suggest that high levels
of Hsp70 could protect cells from HIV-1-specific cytotoxicity
and reduce virus replication. One interesting possibility is that
stressed cells may be less susceptible to HIV infection. Since
Hsp70 is induced by a variety of physical and biochemical
stressors, including bacterial and viral infection (39), it may be
a factor that, in addition to cytokines (30), determines the
outcome of HIV coinfection with another pathogen.
In summary, our results demonstrate that Hsp70 contributes
to cellular innate anti-HIV immunity by targeting activity of
Vpr. The balance between Vpr and Hsp70 may determine, at
least in part, the level of HIV-1 replication and cytopathology.
The Hsp70-mediated protection may be overwhelmed at late
stages of infection, resulting in significant G2 arrest and high
HIV-1 replication. Understanding the molecular details of
Hsp70 interaction with Vpr could suggest new therapeutic
approaches aimed at inactivating this pathogenic viral protein.
ACKNOWLEDGMENTS
We would like to thank Josephine Sire (INSERM, Marseille, France)
for anti-Vpr antibody, Lee Ratner (Washington University, St. Louis,
Mo.) for providing the muristerone A-inducible gene expression vec-
tors and 293T-632 cell lines, and Richard Vile (Mayo Clinic, Roches-
ter, Minn.) for Hsp70/Myc plasmid. pcDNA-Env(MLV) plasmid en-
coding Env of the amphotropic MLV (from N. Landau) was obtained
through the AIDS Research and Reference Reagent Program, Divi-
sion of AIDS, NIAID, NIH.
FIG. 4. Hsp70 coimmunoprecipitates with Vpr from HIV-1-in-
fected cells. (A) MAGI cells were infected with Vpr-positive (Vpr)
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